肺表面活性物质治疗新生儿呼吸窘迫综合征

目的:探讨肺表面活性物质治疗新生儿呼吸窘迫综合征(NRDS)的有效性及临床价值.方法:用肺表面活性物质首剂120 mg,给药时间为出生后3～16 h,平均(5.9±3.2) h,12 h后再用120 mg.分右侧卧、左侧卧、平卧3个体位各1/3剂量,每注入1/3剂量后用复苏气囊供氧1～3 min,使药液在肺内均匀分布,约10 min完成注药过程.结果:用药后即刻症状和体征改善,血气分析明显好转,吸入氧浓度降低,48 h内X线胸片明显改善.结论:肺表面活性物质对NRDS疗效肯定,在改善氧气交换和肺部病变方面发挥重要作用.

Clinical Observation on Curing Neonatal Respiratory Distress Syndrome with Pulmonary Sunfactant

Objective:To study the efficacy and clinical value of pulmonary surfactant (curosurf) replacement therapy in newborn infants with respiratory distress syndrome (NRDS). Method:In the 15 cases of NRDS cured with pulmonary sunfactant, we observed the changes of clinical manifestations, the results of blood gas, fraction of inspiratory oxygen (FiO_2 )and X-ray presentations of lungs after treatment. Results:The symptoms and signs of patients were improved quickly. The results of blood gas analysis were also improved, FiO_2 decreased remarkably, the X-ray pathological changes in the breast of patients were improved evidently. Conclusion:Pulmonary sunfactant has definite effect on neonatal respiratory distress syndrome and plays an important role in improving oxygen exchange and pathological changes in the lungs.